Sally Adams
Direktor/Vorstandsmitglied bei Scancell Ltd.
Vermögen: 8 792 $ am 30.04.2024
Profil
Sally Elizabeth Adams is currently a Director & Development Director at Scancell Ltd.
She previously worked as an Executive Director & Chief Development Officer at Scancell Holdings Plc, a Development Director at Neures Ltd., and Head-Neurology & Virology at Ligand UK Ltd.
Adams holds a doctorate from Imperial College London and a graduate degree from the University of Cambridge.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
SCANCELL HOLDINGS PLC
0,01% | 19.12.2023 | 78 714 ( 0,01% ) | 8 792 $ | 30.04.2024 |
Aktive Positionen von Sally Adams
| Unternehmen | Position | Beginn |
|---|---|---|
Scancell Ltd.
 Scancell Ltd. Miscellaneous Commercial ServicesCommercial Services Scancell Ltd. researches and develops techniques for isolating foetal cells from a maternal blood sample. The company was founded by Lindy Durrant in 1997 and is headquartered in Nottingham, the United Kingdom. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Sally Adams
| Unternehmen | Position | Ende |
|---|---|---|
| SCANCELL HOLDINGS PLC | Direktor/Vorstandsmitglied | 05.02.2024 |
| VERNALIS | Corporate Officer/Principal | - |
| Neures Ltd. | Corporate Officer/Principal | - |
Ausbildung von Sally Adams
| Imperial College London | Doctorate Degree |
| University of Cambridge | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SCANCELL HOLDINGS PLC | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Ligand UK Ltd.
 Ligand UK Ltd. Pharmaceuticals: MajorHealth Technology Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1988 and is headquartered in Winnersh, the United Kingdom. | Health Technology |
Scancell Ltd.
Scancell Ltd. Miscellaneous Commercial ServicesCommercial Services Scancell Ltd. researches and develops techniques for isolating foetal cells from a maternal blood sample. The company was founded by Lindy Durrant in 1997 and is headquartered in Nottingham, the United Kingdom. | Commercial Services |
| Neures Ltd. |
